Navigation Links
Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008
Date:1/31/2008

UNION CITY, Calif., Jan. 31 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fiscal quarter ended December 31, 2007.
Highlights for the third quarter of fiscal 2008 include:

-- Revenues of $25.7 million, up 17% over last year's comparable quarter.

-- Medical market sales of $6.0 million, up 29% over last year's

comparable quarter.

-- Piccolo instrument sales of 238 units, up 45% over last year's

comparable quarter.

-- Veterinary hematology instrument sales of 301 units, up 44% over last

year's comparable quarter.

-- Veterinary reagent disc sales of $11.4 million, up 30% over last

year's comparable quarter.

-- Total medical and veterinary reagent disc sales of $14.3 million

compared to $11.3 million in the same period last year, up 26% over

last year's comparable quarter.

-- Operating income of $4.4 million, up 24% over last year's comparable

quarter.

-- Net income of $3.2 million, up 15% over last year's comparable

quarter.

-- Diluted EPS: $0.14 versus $0.13 in the same period last year.

-- Cash, cash equivalents and short-term investments as of December 31,

2007 of $55.8 million, up 32% compared to December 31, 2006.

Quarterly Results: For the fiscal quarter ended December 31, 2007, Abaxis reported revenues of $25.7 million, as compared with revenues of $22.0 million for the comparable period last year, an increase of 17 percent. Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $3.1 million, or 15 percent over the same period last year. The company reported net income of $3.2 million, compared to $2.8 million for the same period last year. The company's effective tax rate in the quarter ended December 31, 2007 was 35 percent, compared to 31 percent for the same period last year. The company reported diluted net income per share of $0.14 (calculated based on 22,359,000 shares) in the third quarter of fiscal 2008, compared to $0.13 per share (calculated based on 21,939,000 shares) for the same period last year.

Nine-Month Results: For the nine-month period ended December 31, 2007, Abaxis reported revenues of $73.8 million, as compared with revenues of $63.4 million for the comparable period last year, an increase of 16 percent. Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $9.3 million, or 16 percent over the same period last year. The company reported net income of $9.2 million, compared to $7.3 million for the same period last year. The company's effective tax rate in both nine-month periods was 37 percent. The company reported diluted net income per share of $0.41 (calculated based on 22,208,000 shares), compared to $0.33 per share (calculated based on 21,871,000 shares) for the same period last year.

Other Reported Information: Reagent disc and hematology reagent revenues for the third quarter of fiscal 2008 were $15.3 million, up 25 percent over the $12.2 million reported in the same period last year. During the quarter, the company sold a total of 1,212,000 medical and veterinary reagent discs, an increase of 21 percent compared to a total of 1,005,000 medical and veterinary reagent discs sold during the same period last year. Total sales in the medical market for the third quarter of fiscal 2008 were $6.0 million, an increase of 29 percent over last year's comparable quarter. Medical sales in North America, excluding sales to the U.S. government, during the third quarter of fiscal 2008 were $4.2 million, an increase of 25 percent over last year's comparable quarter. Total sales in the veterinary market for the third quarter of fiscal 2008 were $18.1 million, up 11 percent over last year's comparable quarter. Additionally, veterinary reagent disc sales for the third quarter of fiscal 2008 were $11.4 million, an increase of 30 percent compared to the same period last year. The company ended the quarter with $55.8 million in cash, cash equivalents and short-term investments.

Clint Severson, chairman and chief executive officer of Abaxis, commented, "We are pleased with the results of our third quarter and the nine-month period. The results of the quarter represent the 21st consecutive quarter of profitability. We are achieving real traction in the medical market and we are dedicated to providing the highest level of customer service to our end-user clients. We are particularly pleased with the continued success of our distribution partners in placing 191 Piccolo instruments throughout the medical industry during the quarter compared to 94 in the comparable quarter last year."

"Reagent disc unit sales growth of 21% for the quarter of our combined veterinary and medical reagent discs versus the comparable quarter last year is also gratifying. This marks the sixth consecutive quarter of disc sales exceeding one million units. We are also gratified with the granting of waived status under CLIA regulations for many of our medical reagent discs. The nine CLIA-waived panels now on the Abaxis menu represents more than 90% of all general chemistries ordered in the United States. Our products provide a wider segment of the medical profession to conduct comprehensive health screenings at the point of care. We believe that the timeliness of achieving lab-accurate results at the point-of-care will result in more efficient care and better patient outcomes."

Mr. Severson concluded, "Going forward, we believe that we are well positioned for continued growth. The financial condition of the company is very strong with a growing cash position of $55.8 million, no long-term debt and leading-edge technology. We believe that both the veterinary and medical segments have considerable growth opportunities in the future and we are committed to becoming the leading provider of point-of-care blood analysis systems. We know that there will be future challenges to overcome, but we believe we have the people, products and technology to meet our future goals."

Conference Call

Abaxis has scheduled a conference call to discuss its results at 4:15 p.m. ET on January 31, 2008. Participants can dial (877) 356-5706 or (706) 643-0580 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com. A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (800) 642-1687 or (706) 645-9291, access code 32155678, through February 2, 2008. This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Use of Non-GAAP Financial Measures

To supplement its financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share. This non-GAAP financial presentation is not a measurement of performance under GAAP in the United States of America. Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in our conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks involved in carrying of inventory and other risks detailed from time to time in Abaxis' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Financial Tables on Following Pages

ABAXIS, INC.

Condensed Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenues $25,690 $22,018 $73,813 $63,413

Cost of revenues 12,081 10,439 33,331 28,839

Gross profit 13,609 11,579 40,482 34,574

Operating expenses:

Research and development 1,629 1,495 5,104 4,731

Sales and marketing 6,056 5,302 17,666 15,306

General and administrative 1,571 1,262 4,760 4,232

Total operating expenses 9,256 8,059 27,530 24,269

Income from operations 4,353 3,520 12,952 10,305

Interest and other income (expense),

net 552 491 1,580 1,194

Income before income taxes 4,905 4,011 14,532 11,499

Income tax provision 1,700 1,235 5,341 4,208

Net income $3,205 $2,776 $9,191 $7,291

Net income per share:

Basic net income per share $0.15 $0.13 $0.43 $0.35

Diluted net income per share $0.14 $0.13 $0.41 $0.33

Shares used in the calculation of net

income per share:

Weighted average common shares

outstanding - basic 21,561 20,766 21,441 20,547

Weighted average common shares

outstanding - diluted 22,359 21,939 22,208 21,871

ABAXIS, INC.

Condensed Balance Sheets

(Unaudited and in thousands)

December 31, March 31,

2007 2007

Current assets:

Cash and cash equivalents $11,792 $10,183

Short-term investments 43,966 35,028

Trade receivables, net 20,862 16,929

Inventories, net 18,020 14,813

Prepaid expenses 677 1,321

Net deferred tax asset - current 4,133 8,979

Total current assets 99,450 87,253

Property and equipment, net 13,982 12,662

Intangible assets, net 394 450

Other assets 19 38

Net deferred tax asset - non-current 2,469 2,312

Total assets $116,314 $102,715

Current liabilities:

Accounts payable $7,047 $6,505

Accrued payroll and related expenses 3,587 3,830

Other accrued liabilities 1,422 1,169

Deferred revenue 780 917

Warranty reserve 1,157 315

Total current liabilities 13,993 12,736

Non-current liabilities:

Deferred rent 320 391

Deferred revenue 1,210 1,244

Warranty reserve 496 532

Total non-current liabilities 2,026 2,167

Shareholders' equity:

Common stock 106,574 103,282

Accumulated deficit (6,279) (15,470)

Total shareholders' equity 100,295 87,812

Total liabilities and shareholders'

equity $116,314 $102,715

Non-GAAP Operating Income Per Share

(In thousands, except per share data)

Three Months Ended Nine Months Ended

December 31, December 31,

2007 2006 2007 2006

Shares used in the calculation

of operating income per share

(non-GAAP):

Weighted average common shares

outstanding - basic 21,561 20,766 21,441 20,547

Weighted average common shares

outstanding - diluted 22,359 21,939 22,208 21,871

Non-GAAP operating income per

share - basic $0.20 $0.17 $0.60 $0.50

Non-GAAP operating income per

share - diluted $0.19 $0.16 $0.58 $0.47

Revenues by Geographic Region

(In thousands)

Three Months Ended Nine Months Ended

December 31, December 31,

2007 2006 2007 2006

North America $21,628 $18,221 $61,868 $52,652

International 4,062 3,797 11,945 10,761

Total revenues $25,690 $22,018 $73,813 $63,413

Revenues by Customer Group

(In thousands)

Three Months Ended Nine Months Ended

December 31, December 31,

2007 2006 2007 2006

Medical Market $6,005 $4,656 $16,455 $12,506

Veterinary Market 18,073 16,312 52,498 47,013

Other 1,612 1,050 4,860 3,894

Total revenues $25,690 $22,018 $73,813 $63,413


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abaxis to Present at the CL King Best Ideas Conference 2007
2. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
3. Abaxis to Present at the 2007 UBS Global Life Science Conference
4. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
5. Abaxis to Report Second Quarter Fiscal 2008 Financial Results Wednesday, October 24, 2007
6. Abaxis Announces Appointment of New Distribution Partner in Japan
7. Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel
8. Abaxis, Inc. to Present at the Fifth Annual Sidoti & Company Emerging Growth Conference
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: